GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (NAS:GLPG) » Definitions » Cyclically Adjusted PB Ratio

GLPG (Galapagos NV) Cyclically Adjusted PB Ratio : 0.74 (As of May. 30, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Galapagos NV Cyclically Adjusted PB Ratio?

As of today (2025-05-30), Galapagos NV's current share price is $29.09. Galapagos NV's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $39.57. Galapagos NV's Cyclically Adjusted PB Ratio for today is 0.74.

The historical rank and industry rank for Galapagos NV's Cyclically Adjusted PB Ratio or its related term are showing as below:

GLPG' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.58   Med: 1.5   Max: 11.86
Current: 0.7

During the past years, Galapagos NV's highest Cyclically Adjusted PB Ratio was 11.86. The lowest was 0.58. And the median was 1.50.

GLPG's Cyclically Adjusted PB Ratio is ranked better than
65.28% of 671 companies
in the Biotechnology industry
Industry Median: 1.49 vs GLPG: 0.70

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Galapagos NV's adjusted book value per share data for the three months ended in Mar. 2025 was $45.081. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $39.57 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Galapagos NV Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Galapagos NV's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Cyclically Adjusted PB Ratio Chart

Galapagos NV Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.75 2.26 1.49 1.16 0.74

Galapagos NV Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.89 0.68 0.75 0.74 0.63

Competitive Comparison of Galapagos NV's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Galapagos NV's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galapagos NV's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galapagos NV's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Galapagos NV's Cyclically Adjusted PB Ratio falls into.


;
;

Galapagos NV Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Galapagos NV's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=29.09/39.57
=0.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galapagos NV's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Galapagos NV's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=45.081/134.3475*134.3475
=45.081

Current CPI (Mar. 2025) = 134.3475.

Galapagos NV Quarterly Data

Book Value per Share CPI Adj_Book
201506 12.796 100.107 17.173
201509 12.048 100.245 16.147
201512 10.175 100.572 13.592
201603 17.700 101.653 23.393
201606 17.784 102.267 23.363
201609 17.199 102.118 22.627
201612 17.302 102.614 22.653
201703 17.299 103.972 22.353
201706 23.613 103.902 30.532
201709 0.000 104.170 0.000
201712 23.512 104.804 30.140
201803 21.644 105.419 27.584
201806 20.154 106.063 25.529
201809 25.534 106.618 32.175
201812 25.363 107.252 31.771
201903 24.325 107.876 30.294
201906 23.566 107.896 29.343
201909 45.068 107.470 56.339
201912 49.410 108.065 61.427
202003 48.414 108.550 59.920
202006 47.859 108.540 59.238
202009 48.889 108.441 60.568
202012 49.664 108.511 61.489
202103 49.091 109.522 60.219
202106 48.975 110.305 59.650
202109 46.990 111.543 56.597
202112 45.564 114.705 53.367
202203 44.400 118.620 50.287
202206 42.569 120.948 47.285
202209 40.460 124.120 43.794
202212 40.645 126.578 43.140
202303 41.668 126.528 44.243
202306 42.483 125.973 45.307
202309 42.458 127.083 44.885
202312 46.263 128.292 48.447
202403 47.753 130.552 49.141
202406 47.540 130.691 48.870
202409 48.213 130.968 49.457
202412 46.033 132.346 46.729
202503 45.081 134.348 45.081

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Galapagos NV  (NAS:GLPG) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Galapagos NV Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Galapagos NV's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Galapagos NV Business Description

Industry
Address
Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.